Best Practice & Research Clinical Rheumatology
Volume 23, Issue 4 , Pages 495-506 , August 2009

Lupus arthritis

References 

  1. Fessel WJ. Systemic lupus erythematosus in the community. Incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch Intern Med. 1974 Dec;134(6):1027–1035
  2. Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. JAMA. 1964 Oct 12;190:104–111
  3. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992 Sep;10(5):527–539
  4. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res. 1995 Sep;8(3):137–145
  5. Sestak AL, Nath SK, Kelly JA, et al. Patients with familial and sporadic onset SLE have similar clinical profiles but vary profoundly by race. Lupus. 2008 Nov;17(11):1004–1009
  6. Labowitz R, Schumacher HR. Articular manifestations of systemic lupus erythematosus. Ann Intern Med. 1971 Jun;74(6):911–921
  7. Hoffman IE, Peene I, Meheus L, et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis. 2004 Sep;63(9):1155–1158
  8. Lee SS. Symptomatic unilateral sacroiliitis in systemic lupus erythematosus. Lupus. 1995 Aug;4(4):328–329
  9. Kohli M, Bennett RM. Sacroiliitis in systemic lupus erythematosus. J Rheumatol. 1994 Jan;21(1):170–171
  10. Vivas J, Tiliakos NA. Sacroiliitis in male systemic lupus erythematous. Scand J Rheumatol. 1985;14(4):441
  11. Wallace DJ. The Musculoskeletal system. In: Dubois lupus erythematosus. 2007;p. 647–662
  12. Klemp P, Meyers OL, Keyzer C. Atlanto-axial subluxation in systemic lupus erythematosus: a case report. S Afr Med J. 1977 Aug 13;52(8):331–332
  13. Isenberg DA, Tookman A, White AG, et al. Erosive rheumatoid arthritis co-existing with systemic lupus erythematosus. A report of a case, also showing atlanto-axial subluxation. Clin Rheumatol. 1982 Sep;1(3):216–220
  14. Babini SM, Cocco JA, Babini JC, et al. Atlantoaxial subluxation in systemic lupus erythematosus: further evidence of tendinous alterations. J Rheumatol. 1990 Feb;17(2):173–177
  15. Santiago MB, Galvao V. Jaccoud arthropathy in systemic lupus erythematosus: analysis of clinical characteristics and review of the literature. Medicine (Baltimore). 2008 Jan;87(1):37–44
  16. Reilly PA, Evison G, McHugh NJ, Maddison PJ. Arthropathy of hands and feet in systemic lupus erythematosus. J Rheumatol. 1990 Jun;17(6):777–784
  17. Esdaile JM, Danoff D, Rosenthall L, Gutkowski A. Deforming arthritis in systemic lupus erythematosus. Ann Rheum Dis. 1981 Apr;40(2):124–126
  18. Alarcon-Segovia D, Abud-Mendoza C, Diaz-Jouanen E, et al. Deforming arthropathy of the hands in systemic lupus erythematosus. J Rheumatol. 1988 Jan;15(1):65–69
  19. Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 2001 Jan;60(1):67–68
  20. van Vugt RM, Derksen RH, Kater L, Bijlsma JW. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis. 1998 Sep;57(9):540–544
  21. Morley KD, Leung A, Rynes RI. Lupus foot. Br Med J (Clin Res Ed). 1982 Feb 20;284(6315):557–558
  22. Paredes JG, Lazaro MA, Citera G, et al. Jaccoud's arthropathy of the hands in overlap syndrome. Clin Rheumatol. 1997 Jan;16(1):65–69
  23. Kramer L, Ruderman JE, Dubois EL, Friou GJ. Deforming, nonerosive arthritis of the hands in chronic systemic lupus erythematosus (SLE). Arthritis Rheum. 1970;13(3):329–330
  24. Russell AS, Percy JS, Rigal WM, Wilson GL. Deforming arthropathy in systemic lupus erthematosus. Ann Rheum Dis. 1974 May;33(3):204–209
  25. Franceschini F, Cretti L, Quinzanini M, et al. Deforming arthropathy of the hands in systemic lupus erythematosus is associated with antibodies to SSA/Ro and to SSB/La. Lupus. 1994 Oct;3(5):419–422
  26. Pipili C, Sfritzeri A, Cholongitas E. Deforming arthropathy in SLE: review in the literature apropos of one case. Rheumatol Int. 2008 Dec 9;
  27. Panush RS, Edwards NL, Longley S, Webster E. ‘Rhupus’ syndrome. Arch Intern Med. 1988 Jul;148(7):1633–1636
  28. Mezcua-Guerra LM, Springall R, Marquez-Velasco R, et al. Presence of antibodies against cyclic citrullinated peptides in patients with ‘rhupus’: a cross-sectional study. Arthritis Res Ther. 2006;8(5):R144
  29. Damian-Abrego GN, Cabiedes J, Cabral AR. Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy. Lupus. 2008;17(4):300–304
  30. Chan MT, Owen P, Dunphy J, et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol. 2008 Jan;35(1):77–83
  31. Isenberg DA, Steiner G, Smolen JS. Clinical utility and serological connections of anti-RA33 antibodies in systemic lupus erythematosus. J Rheumatol. 1994 Jul;21(7):1260–1263
  32. Iagnocco A, Ossandon A, Coari G, et al. Wrist joint involvement in systemic lupus erythematosus. An ultrasonographic study. Clin Exp Rheumatol. 2004 Sep;22(5):621–624
  33. Boutry N, Hachulla E, Flipo RM, et al. MR imaging findings in hands in early rheumatoid arthritis: comparison with those in systemic lupus erythematosus and primary Sjogren syndrome. Radiology. 2005 Aug;236(2):593–600
  34. Aydin S, Atagunduz P, Filippucci E, et al. A rare case of spontaneous, bilateral Achilles tendon rupture in systemic lupus erythematosus and a review of the literature. Lupus. 2008 Nov;17(11):1051–1052
  35. Cooney LM, Aversa JM, Newman JH. Insidious bilateral infrapatellar tendon rupture in a patient with systemic lupus erythematosus. Ann Rheum Dis. 1980 Dec;39(6):592–595
  36. Furie RA, Chartash EK. Tendon rupture in systemic lupus erythematosus. Semin Arthritis Rheum. 1988 Nov;18(2):127–133
  37. Muniain M, Spilberg I. Opera-glass deformity and tendon rupture in a patient with systemic lupus erythematosus. Clin Rheumatol. 1985 Sep;4(3):335–339
  38. Pritchard CH, Berney S. Patellar tendon rupture in systemic lupus erythematosus. J Rheumatol. 1989 Jun;16(6):786–788
  39. Twining RH, Marcus WY, Garey JL. Tendon rupture in systemic lupus erythematosus. JAMA. 1964 Aug 3;189:377–378
  40. Potasman I, Bassan HM. Multiple tendon rupture in systemic lupus erythematosus: case report and review of the literature. Ann Rheum Dis. 1984 Apr;43(2):347–349
  41. Goldenberg DL, Cohen AS. Synovial membrane histopathology in the differential diagnosis of rheumatoid arthritis, gout, pseudogout, systemic lupus erythematosus, infectious arthritis and degenerative joint disease. Medicine (Baltimore). 1978 May;57(3):239–252
  42. Pekin TJ, Zvaifler NJ. Synovial fluid findings in systemic lupus erythematosus (SLE). Arthritis Rheum. 1970 Nov;13(6):777–785
  43. Leskinen RH, Skrifvars BV, Laasonen LS, Edgren KJ. Bone lesions in systemic lupus erythematosus. Radiology. 1984 Nov;153(2):349–352
  44. Weissman BN, Rappoport AS, Sosman JL, Schur PH. Radiographic findings in the hands in patients with systemic lupus erythematosus. Radiology. 1978 Feb;126(2):313–317
  45. Wright S, Filippucci E, Grassi W, et al. Hand arthritis in systemic lupus erythematosus: an ultrasound pictorial essay. Lupus. 2006;15(8):501–506
  46. Huang JL, Hung JJ, Wu KC, et al. Septic arthritis in patients with systemic lupus erythematosus: salmonella and nonsalmonella infections compared. Semin Arthritis Rheum. 2006 Aug;36(1):61–67
  47. Picillo U, Italian G, Marcialis MR, et al. Bilateral femoral osteomyelitis with knee arthritis due to Salmonella enteritidis in a patient with systemic lupus erythematosus. Clin Rheumatol. 2001;20(1):53–56
  48. Lim E, Koh WH, Loh SF, et al. Non-typhoidal salmonellosis in patients with systemic lupus erythematosus. A study of fifty patients and a review of the literature. Lupus. 2001;10(2):87–92
  49. Quismorio FP, Dubois EL. Septic arthritis in systemic lupus erythematosus. J Rheumatol. 1975 Mar;2(1):73–82
  50. Yun JE, Lee SW, Kim TH, et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol. 2002 Mar;20(2):127–132
  51. Dubois EL, Cozen L. Avascular (aseptic) bone necrosis associated with systemic lupus erythematosus. JAMA. 1960 Oct 22;174:966–971
  52. Gladman DD, Chaudhry-Ahluwalia V, Ibanez D, et al. Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol. 2001 Oct;28(10):2226–2229
  53. Dimant J, Ginzler EM, Diamond HS, et al. Computer analysis of factors influencing the appearance of aseptic necrosis in patients with SLE. J Rheumatol. 1978;5(2):136–141
  54. Fialho SC, Bonfa E, Vitule LF, et al. Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus. 2007;16(4):239–244
  55. Ibanez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol. 2005 May;32(5):824–827
  56. Cozen L, Wallace DJ. Avascular necrosis in systemic lupus erythematosus: clinical associations and a 47-year perspective. Am J Orthop. 1998 May;27(5):352–354
  57. Campos LM, Kiss MH, D'Amico EA, Silva CA. Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Lupus. 2003;12(11):820–826
  58. Mok CC, Lau CS, Wong RW. Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol. 1998 Aug;37(8):895–900
  59. Mok MY, Farewell VT, Isenberg DA. Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies?. Ann Rheum Dis. 2000 Jun;59(6):462–467
  60. Rascu A, Manger K, Kraetsch HG, et al. Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?. Lupus. 1996 Aug;5(4):323–327
  61. Alarcon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore). 1989 Nov;68(6):353–365
  62. Tektonidou MG, Malagari K, Vlachoyiannopoulos PG, et al. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum. 2003 Mar;48(3):732–736
  63. Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002 Oct;32(2):94–124
  64. Nagasawa K, Tada Y, Koarada S, et al. Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant. Lupus. 2006;15(6):354–357
  65. Klippel JH, Gerber LH, Pollak L, Decker JL. Avascular necrosis in systemic lupus erythematosus. Silent symmetric osteonecroses. Am J Med. 1979 Jul;67(1):83–87
  66. Mont MA, Marulanda GA, Jones LC, et al. Systematic analysis of classification systems for osteonecrosis of the femoral head. J Bone Joint Surg Am. 2006 Nov;88(Suppl. 3):16–26
  67. Marker DR, Seyler TM, McGrath MS, et al. Treatment of early stage osteonecrosis of the femoral head. J Bone Joint Surg Am. 2008 Nov;90(Suppl. 4):175–187
  68. Petrigliano FA, Lieberman JR. Osteonecrosis of the hip: novel approaches to evaluation and treatment. Clin Orthop Relat Res. 2007 Dec;465:53–62
  69. Wallace DJ, Metzger AL, Klinenberg JR. NSAID usage patterns by rheumatologists in the treatment of SLE. J Rheumatol. 1989 Apr;16(4):557–560
  70. Ostensen M, Villiger PM. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus. 2001;10(3):135–139
  71. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther. 2007 Jul;20(4):160–174
  72. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002 Apr 11;416(6881):603–607
  73. Williams HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol. 1994 Aug;21(8):1457–1462
  74. Meinao IM, Sato EI, Andrade LE, et al. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus. 1996 Jun;5(3):237–241
  75. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med. 1991 Jan 17;324(3):150–154
  76. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998;7(2):80–85
  77. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2008 Dec 22;
  78. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum. 1996 Dec;39(12):1951–1960
  79. Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999 Jun;26(6):1275–1279
  80. Fortin PR, Abrahamowicz M, Ferland D, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008 Dec 15;59(12):1796–1804
  81. Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis. 1997 Jun;56(6):382–385
  82. Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol. 1998 Feb;25(2):243–246
  83. Wilson K, Abeles MA. 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1994 Sep;21(9):1674–1677
  84. Tam LS, Li EK, Wong CK, et al. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus. 2004;13(8):601–604
  85. Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus. 2001;10(7):480–483
  86. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006 Aug;70(4):732–742
  87. Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus. 2005;14(Suppl. 1):s33–s38
  88. Sztejnbok M, Stewart A, Diamond H, Kaplan D. Azathioprine in the treatment of systemic lupus erythematosus. A controlled study. Arthritis Rheum. 1971 Sep;14(5):639–645
  89. Ginzler E, Sharon E, Diamond H, Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum. 1975 Jan;18(1):27–34
  90. Sharon E, Kaplan D, Diamond HS. Exacerbation of systemic lupus erythematosus after withdrawal of azathioprine therapy. N Engl J Med. 1973 Jan 18;288(3):122–124
  91. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 Nov 24;353(21):2219–2228
  92. Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005 Oct;10(5):504–510
  93. Bijl M, Horst G, Bootsma H, et al. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis. 2003 Jun;62(6):534–539
  94. Karim MY, Alba P, Cuadrado MJ, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford). 2002 Aug;41(8):876–882
  95. Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum. 1995 Dec;38(12):1826–1831
  96. Petri MA, Lahita RG, Van Vollenhoven RF, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002 Jul;46(7):1820–1829
  97. Petri MA, Mease PJ, Merrill JT, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004 Sep;50(9):2858–2868
  98. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Nov;46(11):2924–2927
  99. Tokuda M, Kurata N, Mizoguchi A, et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum. 1994 Apr;37(4):551–558
  100. Duddridge M, Powell RJ. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis. 1997 Nov;56(11):690–692
  101. Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev. 2009 Feb;8(4):343–348
  102. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109
  103. Ramsey-Goldman R, Schilling EM, Dunlop D, et al. A pilot study on the effects of exercise in patients with systemic lupus erythematosus. Arthritis Care Res. 2000 Oct;13(5):262–269
  104. Karlson EW, Liang MH, Eaton H, et al. A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum. 2004 Jun;50(6):1832–1841
  105. Nalebuff EA. Surgery of systemic lupus erythematosus arthritis of the hand. Hand Clin. 1996 Aug;12(3):591–602

PII: S1521-6942(09)00044-8

doi: 10.1016/j.berh.2009.04.003

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 4 , Pages 495-506 , August 2009

Article Tools

* Image Usage & Resolution